Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

• US 7,364,862 B2
• Filed: 08/30/2004
• Issued: 04/29/2008
• Est. Priority Date: 10/19/1998
• Status: Expired due to Fees

• Current Assignee: Diazyme Laboratories, Inc. (General Atomics, Inc.)
• Original Assignee: Diadexus, Inc.
• Inventors: Ali, Shujath M., Salceda, Susana, Cafferkey, Robert, Recipon, Herve, Sun, Yongming
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US10/929,973
• Publication Number:
  US 20050147556A1
• Time in Patent Office: 1,338 Days
• Field of Search: 435/7.1, 435/7.23, 424/178.1, 530/387.1
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer.

Claims

1. A method for diagnosing the presence of prostate cancer in a patient comprising:

(a) measuring levels of CSG in prostate, tissues or bodily fluids in a patient; and

(b) comparing the measured levels of CSG with levels of CSG in prostate, tissues or bodily fluids from a non-cancerous control, wherein an increase in measured levels of CSG in said patient versus non-cancerous control is associated with the presence of prostate cancer,

wherein said CSG comprises SEQ ID NO;

2.

2. A method of imaging prostate cancer in a patient comprising administering to the patient an antibody which specifically binds a CSG comprising SEQ ID NO:

2.

3. The method of claim 2 wherein said antibody is labeled with paramagnetic ions or a radioisotope.